Showing results (241-250 of 268) with videos related to
Sort By:
Pageof 27
The New England Journal of Medicine|March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 TrialYelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohortsAlexander Quaas, Hedde D Biesma, Anna D Wagner, et al.Clinical Nutrition ESPEN|June 26, 2025
Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors-A randomized clinical trial (IKF-010)Thorsten Oliver Goetze, Ralf-Dieter Hofheinz, Ingeborg Roetzer, et al.JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.Oncotarget|December 5, 2014
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignanciesMatthias Scheffler, Marc Bos, Masyar Gardizi, et al.Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2012
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancerHans-Ulrich Schildhaus, Lukas C Heukamp, Sabine Merkelbach-Bruse, et al.Journal of Cancer Research and Clinical Oncology|October 14, 2022
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemicVolker Arndt, Daniela Doege, Stefan Fröhling, et al.Pageof 27